<DOC>
	<DOCNO>NCT01874860</DOCNO>
	<brief_summary>The purpose study determine use preventive treatment Doxycycline ( anti-biotic ) capsule , sunscreen SPF 30 , Hydrocortisone 1 % cream moisturizer help reduce incidence severity skin rash associate Cetuximab ( ErbituxÂ® ) compare receive standard care treatment skin rash .</brief_summary>
	<brief_title>Skin Rash Study Before Chemotherapy Colorectal &amp; Head Neck Cancer Patients</brief_title>
	<detailed_description>Of 100 subject participate study , 50 extensive treatment group 50 standard care group . Subjects extensive treatment group use Doxycycline capsule , 100 mg , take twice daily , sunscreen SPF 30 high , moisturizer applied face , hand , foot , neck , back , chest morning sunscreen , hydrocortisone 1 % cream apply face , hand , foot , neck , back , chest evening . Subjects start take capsule apply cream three day prior begin cetuximab therapy . They continue regimen take capsule apply cream 8 week . If develop severe skin rash result cetuximab therapy , study doctor may decide reduce amount dose cetuximab receive prescribe medicine accord standard treatment recommendation , he/she would subject participate study . Subjects monitor enrollment , 3 week cetuximab treatment end cetuximab treatment adherence , side effect quality life . The standard care group receive preventive treatment , allow use sunscreen moisturizer desire . They , , monitor enrollment , 3 week cetuximab treatment end cetuximab treatment adherence , side effect quality life . If subject assign group develop severe skin rash , study doctor treat rash accord standard treatment recommendation , may include Hydrocortisone 1 % cream , Doxycycline capsule medication . There follow-Up period extensive treatment standard care group . At 6 month , 12 month , 18 month 24 month , end subject 's 8 week study treatment period , contact telephone discuss routine clinic visit .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Sunscreening Agents</mesh_term>
	<criteria>1 . Age great equal 18 year 2 . Diagnosis colorectal head neck cancer 3 . Receipt least one dose cetuximab study time period 1 . Prior cetuximab treatment within 6 month study initiation 2 . Current treatment tyrosine kinase inhibitor 3 . Patients pregnant incarcerate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>